Invivogen
Menu

Anti-hCTLA4-hIgG4 (S228P)

Anti-hCTLA4-hIgG4 (S228P) Unit size Cat. code Docs Qty Price
Human CTLA4 (ipilimumab) antibody - Human IgG4 (S228P)
100 µg
hctla4-mab14
+-
$325.00

Human CTLA4 (ipilimumab) antibody - Human IgG4 (S228P)

Anti-hCTLA4-hIgG4 (S228P) features the constant region of the human IgG4 (S228P) isotype and the variable region of ipilimumab. Ipilimumab is a fully human IgG1 monoclonal antibody that targets CTLA-4 (also known as CD152), a negative regulator of T cell activation.

By binding CTLA-4, ipilimumab inhibits negative signals that physiologically downregulate T cell activation and exerts its therapeutic activity by upregulating the antitumor activity of T lymphocytes [1, 2].

In addition, Ipilimumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) and TNF-α production [3]. Ipilimumab has been approved by the FDA for the treatment of unresectable or metastatic melanoma. Ipilimumab is undergoing clinical trials for other types of cancers, including lung cancer [4].

Anti-hCTLA4-hIgG4 (S228P) contains an engineered hinge region mutation (S228P) designed to prevent exchange of IgG4 molecules.

Anti-hCTLA4-hIgG4 (S228P) was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

 

References:

1. Grosso JF. & Jure-Kunkel MN., 2013. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13:5.
2. Maio M. et al., 2013. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol. 25(2):166-72.
3. Laurent S.. et al., 2013. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med. 11:108.
4. Tomasini P., 2012. Ipilimumab: its potential in nonsmall cell lung cancer. Ther Adv Med Oncol. 4(2): 43–50.

Back to the top

Specifications

Specificity: Targets cells expressing human CTLA-4

Clonality: Monoclonal antibody

Isotype: Human IgG4 (S228P)

Source: CHO cells

Purity: Purified by affinity chromatography with protein G

Quality control:

  • Binding of Anti-hCTLA4-hIgG4 (S228P) to human CTLA-4 has been tested using flow cytometry.
  • The complete sequence of this antibody has been verified.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top

Contents

  • 100 µg purified anti-hCTLA4-hIgG4 (S228P) antibody, provided azide-free and lyophilized.

room temperature Product is shipped at room temperature.

store Store lyophilized antibody at -20°C.

stability Lyophilized product is stable for 1 year.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty